Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

  • LAST PRICE
    122.6400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    97.0000/ 1
  • Ask / Lots
    134.5200/ 1
  • Open / Previous Close
    --- / 122.6400
  • Day Range
    ---
  • 52 Week Range
    99.0600
    134.1700
  • Volume
    114

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
JAZZ
Jazz Pharmaceuticals PLC
7.4B
17.3x
-3.53%
CTLT
Catalent Inc
11.1B
-26.9x
---
PRGO
Perrigo Company PLC
3.9B
-26.9x
---
AMRX
Amneal Pharmaceuticals Inc
2.6B
-12.2x
---
NDOI
Endo Inc
1.8B
0.4x
---
RPRX
Royalty Pharma PLC
15.5B
10.4x
+1.83%
As of 2024-11-29

Company Information

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Contact Information

Headquarters
Fifth Fl Waterloo Exchange, Waterloo RoadDUBLIN, Ireland 4
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Bruce Cozadd
President, Chief Operating Officer
Renee Gala
Chief Financial Officer, Executive Vice President
Philip Johnson
Executive Vice President, Global Head of Research and Development
Robert Iannone
Executive Vice President, Chief Legal Officer
Neena Patil

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$7.4B
Revenue (TTM)
$4.0B
Shares Outstanding
60.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.57
EPS
$7.10
Book Value
$60.03
P/E Ratio
17.3x
Price/Sales (TTM)
1.9
Price/Cash Flow (TTM)
6.7x
Operating Margin
16.24%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.